Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus recommendation of “Hold” from the seven research firms that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $21.40.

A number of equities research analysts have commented on the stock. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. HC Wainwright increased their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings cut shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, BTIG Research reissued a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a research report on Friday, March 20th.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of TBPH. AQR Capital Management LLC acquired a new stake in shares of Theravance Biopharma in the 1st quarter worth $101,000. Jane Street Group LLC grew its position in Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 88,540 shares during the period. Creative Planning acquired a new stake in Theravance Biopharma during the second quarter worth about $139,000. American Century Companies Inc. grew its stake in shares of Theravance Biopharma by 6.8% during the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock worth $1,009,000 after purchasing an additional 5,794 shares during the period. Finally, Invesco Ltd. grew its position in Theravance Biopharma by 12.4% during the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,789 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $16.58 on Friday. The business’s fifty day moving average price is $16.50 and its 200-day moving average price is $17.37. The stock has a market capitalization of $854.70 million, a price-to-earnings ratio of 7.54 and a beta of 0.17. Theravance Biopharma has a 1-year low of $10.44 and a 1-year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The firm had revenue of $17.70 million during the quarter. Equities research analysts anticipate that Theravance Biopharma will post 1.54 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.